China Pharma Holdings, Inc.
CPHI
$0.1412
$0.00473.44%
| Weiss Ratings | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Very Weak | |||
| Beta / Standard Deviation | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.46 | |||
| Price History | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -43.57% | |||
| 30-Day Total Return | -32.73% | |||
| 60-Day Total Return | -32.12% | |||
| 90-Day Total Return | -29.54% | |||
| Year to Date Total Return | -40.92% | |||
| 1-Year Total Return | -61.85% | |||
| 2-Year Total Return | -91.65% | |||
| 3-Year Total Return | -99.14% | |||
| 5-Year Total Return | -99.31% | |||
| 52-Week High % Change | -66.71% | |||
| 52-Week Low % Change | 13.75% | |||
| Price | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.41 | |||
| 52-Week Low Price | $0.12 | |||
| 52-Week Low Price (Date) | Apr 07, 2025 | |||
| 52-Week High Price (Date) | May 20, 2024 | |||
| Valuation | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 4.45M | |||
| Enterprise Value | 7.42M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.28 | |||
| Earnings Per Share Growth | -74.78% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.70 | |||
| Price/Book (Q) | 0.57 | |||
| Enterprise Value/Revenue (TTM) | 1.64 | |||
| Price | $0.14 | |||
| Enterprise Value/EBITDA (TTM) | -3.76 | |||
| Enterprise Value/EBIT | -1.62 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 23.07M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 86 89 8668 11730 | |||
| Address | -- | |||
| Website | www.chinapharmaholdings.com | |||
| Country | China | |||
| Year Founded | -- | |||
| Profitability | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -101.32% | |||
| Profit Margin | -104.57% | |||
| Management Effectiveness | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -18.29% | |||
| Return on Equity | -- | |||
| Income Statement | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 4.53M | |||
| Total Revenue (TTM) | 4.53M | |||
| Revenue Per Share | $0.20 | |||
| Gross Profit (TTM) | -1.99M | |||
| EBITDA (TTM) | -1.97M | |||
| EBIT (TTM) | -4.59M | |||
| Net Income (TTM) | -4.74M | |||
| Net Income Avl. to Common (TTM) | -4.74M | |||
| Total Revenue Growth (Q YOY) | -47.25% | |||
| Earnings Growth (Q YOY) | 0.63% | |||
| EPS Diluted (TTM) | -0.28 | |||
| EPS Diluted Growth (Q YOY) | 68.62% | |||
| Balance Sheet | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 626.90K | |||
| Cash Per Share (Q) | $0.03 | |||
| Total Current Assets (Q) | 3.27M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 7.75M | |||
| Current Ratio (Q) | 0.652 | |||
| Book Value Per Share (Q) | $0.24 | |||
| Total Assets (Q) | 14.89M | |||
| Total Current Liabilities (Q) | 5.02M | |||
| Total Debt (Q) | 3.59M | |||
| Total Liabilities (Q) | 7.14M | |||
| Total Common Equity (Q) | 7.75M | |||
| Cash Flow | CPHI - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -291.80K | |||
| Cash from Financing (TTM) | 27.40K | |||
| Net Change in Cash (TTM) | -796.90K | |||
| Levered Free Cash Flow (TTM) | 470.60K | |||
| Cash from Operations (TTM) | -466.40K | |||
